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Abstract
Objective: Nocturnal hypoventilation (NH) is a complication of respiratory involvement in
neuromuscular disorders (NMD) that can evolve into symptomatic daytime hypercapnia if not
treated proactively with non-invasive ventilation. This study aimed to assess whether NH can be
detected in the absence of other signs of nocturnal altered gas exchange.
Methods: We performed nocturnal transcutaneous coupled (tc) pCO2/SpO2 monitoring in 46
consecutive cases of paediatric-onset NMD with a restrictive respiratory defect (forced vital
capacity< 60%). Nocturnal hypoventilation was defined as tcPCO2> 50 mmHg for> 25% of
recorded time, and hypoxemia as tcSpO2< 88% for> 5 minutes. Daytime symptoms and bicar-
bonate were recorded after overnight monitoring.
Results: Twenty-nine of 46 consecutive patients showed NH. Twenty-three patients did not have
nocturnal hypoxemia and 18 were clinically asymptomatic. In 20 patients, PaCO2 in daytime blood
samples was normal. Finally, 13/29 patients with NH had isolated nocturnal hypercapnia without
nocturnal hypoxia, clinical NH symptoms, or daytime hypercapnia.
Conclusions: Paediatric patients with NMD can develop NH in the absence of clinical symptoms
or significant nocturnal desaturation. Therefore, monitoring of NH should be included among
nocturnal respiratory assessments of these patients as an additional tool to determine when to
commence non-invasive ventilation.
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Introduction
Neuromuscular weakness often leads to a
chronic restrictive respiratory deficiency.
This deficiency is characterized by a reduc-
tion in vital capacity (VC), total lung capac-
ity, and functional residual capacity with a
variable course among different disor-
ders.1,2 The first manifestation of chronic
respiratory insufficiency in neuromuscular
disorders (NMD) is nocturnal hypoventila-
tion (NH) occurring in rapid eye movement
sleep. Various definitions of NH have been
proposed, but which definition best relates
to prognosis remains unclear.3,4 In patients
with NMD, a correlation between a reduc-
tion in VC and progression of sleep-
disordered breathing has been shown.5
Because clinical symptoms of NH can be
insidious and not always present, daytime
clinical assessments can be unreliable in
early detection of respiratory failure.6
Early recognition of NH is crucial because,
if undiagnosed and thus untreated by non-
invasive ventilation (NIV), NH can prog-
ress to daytime hypercapnia (partial
carbon dioxide pressure [PaCO2]> 45
mmHg in blood gases1–3) or clinical symp-
toms related to hypoventilation.1,3,7 Prompt
use of NIV is effective in reducing
nocturnal hypoventilation and its progres-
sion towards daytime hypercapnia.8,9
Despite published guidelines, there is still
debate regarding the correct timing to
start NIV10–12. Few studies have specifically
evaluated whether nocturnal hypercapnia is
present in clinically asymptomatic patients
with NMD.13–15 If this is the case, this find-
ing could further expand the indications for
NIV support.
The main aim of this study was to assess
whether the current indicators of impairment
of gas exchange, namely nocturnal hypox-
emia, daytime PaCO2, and clinical symp-
toms, may underestimate the presence of
NH in paediatric-onset NMD.
Patients and methods
We performed a retrospective study of
46 consecutive inpatients with NMD who
were referred to the Neuromuscular Unit
at G. Gaslini Pediatric Institute, Genova
over a 6-year period from 2009 to 2014.
All of the patients had genetically con-
firmed paediatric-onset NMD and a con-
comitant restrictive respiratory deficiency,
defined as a forced vital capacity (FVC)
below 60% of the predicted value. As per
British Thoracic Society guidelines,1 this
threshold is considered an indicator to com-
mence nocturnal respiratory assessment in
NMD. Patients with acute upper or lower
airway infections were excluded. Nocturnal
evaluation was performed during the eve-
ning of the scheduled hospital admission.
The study protocol was approved by
Giannina Gaslini Institute Ethics
Committee in accordance with Italian legis-
lation and according to the principles of the
Helsinki Declaration. No patients’ consent
was required because of the retrospective
nature of the study.
For each patient, we collected clinical
information regarding NMD diagnosis,
age, FVC, presence of scoliosis, and clinical
symptoms of NH. We specifically asked
about the presence of headache, nausea,
sleep quality, and daytime sleepiness.
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FVC was measured using a standard spi-
rometer (Micro Loop; MicroMedical,
Rochester Kent) and analysed using Spida5
software V 1.61 (MicroMedical). Lung func-
tion tests were performed according to
The American Thoracic Society and the
European Respiratory Society guidelines, in
an upright position.16 Nocturnal PCO2 and
SpO2 values were recorded using the SenTec
Digital Monitoring System (SenTec AG,
Therwil, Switzerland), which is able to con-
tinuously measure transcutaneous coupled
PCO2 (tcPCO2) and SpO2 (tcSpO2) from a
single probe. Calibration of the transcutane-
ous monitoring equipment was performed on
the evening before application of the SenTec
sensor. Patients with missing or unreliable
data were not included in the study.
NH was defined as tcPCO2> 50 mmHg
for> 25% of the total sleep time according
to the American Academy of Sleep Medicine
guidelines.17According to the American
College of Chest Physicians definition, sig-
nificant hypoxia was defined as tcSpO2
< 88% for> 5 consecutives minutes of
recording time.18 Mean overnight tcPCO2
and tcSpO2 were also calculated from
the Sentec transcutaneous monitor using
the drift corrected value. The morning after
the overnight sleep study, PaCO2 and bicar-
bonate values from capillary arterial blood
gases were recorded. Daytime hypercapnia
was defined as PaCO2> 45 mmHg.
1–3
Patients with and without NH were com-
pared in terms of age, lung function (FVC),
mean nocturnal tcPCO2 and tcSpO2, pres-
ence of hypoxemia, levels of daytime bicar-
bonate, presence of daytime symptoms, and
presence of daytime hypercapnia.
Finally, among patients who started NIV
because of detection of impairment of gas
exchange, a follow-up nocturnal study was
performed after 6 months. Values of
tcPCO2 and tcSpO2, daytime bicarbonate,
and PaCO2, and the presence of daytime
symptoms were collected and compared
with pre-ventilation values.
Statistical analysis
Data were analysed by GraphPad PrismVR
software version 7.02 (La Jolla, CA, USA).
Descriptive statistics were generated for each
measure. For all of the reported variables, a
test of normality was performed. Variables
that were not normally distributed were
reported as median with 25–75 percentiles.
Comparisons of the clinical characteristics
among each diagnostic group were made
by either ANOVA or the Kruskall–Wallis
test according to the distribution of data.
Comparison of baseline values between
patients with NH and non-NH patients
was performed by either parametric or
non-parametric tests for independent varia-
bles. Similarly, comparison between baseline
and follow-up data among patients undergo-
ing NIV was made by either parametric or
non-parametric tests for dependent varia-
bles. Chi square test was used for compari-
son between categorical values.
Results
The total number of patients who attended
our Unit within the study period was 58.
Twelve patients were excluded either
because of an ongoing acute exacerbation
or because they were affected by a life-
threatening underlying muscular condition.
Study population (n¼ 46; 33 male, 13
female) included 14 patients with
Duchenne muscular dystrophy (DMD), 12
with spinal muscular atrophy type 2 (SMA
2), nine with congenital myopathy (CM),
six with Becker muscular dystrophy
(BMD), and five with congenital muscular
dystrophy (CMD). Median age at nocturnal
evaluation was 14.9 years (11.9–17.1 years).
Age at baseline was significantly different
according to NMD diagnosis (p¼ 0.008);
patients with SMA 2 were the youngest
and those with BMD were the oldest
(Table 1). In 17 of the 46 patients
(7 DMD, 7 SMA 2, 2 BMD, 1 CMD)
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nocturnal gas exchange measures were
within the normal range. Additionally,
these patients also had normal daytime
PaCO2 and bicarbonate levels.
In the remaining 29 patients (9 CM, 7
DMD, 5 SMA 2, 4 CMD, 4 BMD) some
degree of altered nocturnal gas exchange
was present, and these individuals were cat-
egorized as nocturnal hypoventilators.
Within this group, six patients showed
NH with hypoxaemia, while nine had day-
time hypercapnia and high bicarbonate
levels. Eleven patients complained of clini-
cal symptoms of NH as morning headaches
(n¼ 5), daytime sleepiness (n¼ 3), and fre-
quent arousals (n¼ 3). Finally, 13 out of the
29 patients showed isolated nocturnal
hypercapnia (Figure 1).
Mean age was similar in patients
with NH and non-NH patients (p¼ 0.55).
However, mean baseline FVC (p¼ 0.007)
and tcSpO2 (p¼ 0.02) were significantly
lower in patients with NH than in non-
NH patients. Conversely, mean tcPCO2
(p¼ 0.0001) and daytime bicarbonate
(p¼ 0.01) were significantly higher in
patients with NH than in non-NH patients.
As reported above, while no patient had
daytime hypercapnia among non-NH
patients, nine patients with NH had day-
time hypercapnia (Table 2).
All of the 29 patients with indications
for NIV based on daytime hypercapnia
or NH started therapy and were re-
evaluated after 6 months. In 24 patients,
a Pressure Support mode was used, while
five were placed on an Assist Controlled
Pressure Mode because of either
younger age or a more severe muscle
involvement. Twenty-four patients used a
nasal interface (of these, four nasal pil-
lows were used), while five used a full-
face mask.
At 6-months follow-up, there was
an overall significant improvement in noc-
turnal gas exchange (tcPCO2, p< 0.0001;
tcSpO2, p¼ 0.009) and in daytime PaCO2
and bicarbonate levels (p¼ 0.03 and
p¼ 0.01, respectively). Eleven patients who
previously complained of NH symptoms
reported complete resolution of symptoms
(Table 3).
Patients with congenital myopathies had
the lowest baseline tcSpO2. In this group,
non-invasive ventilation was effective for
nocturnal tcSpO2 (p¼ 0.008) and tcPCO2
(p¼ 0.008). Conversely, patients with
DMD only showed improvement in
tcPCO2 (p¼ 0.03) after the start of NIV
treatment. Table 4 shows the baseline dif-
ferences in age and nocturnal gas exchange
according to diagnostic category.
Table 1. Clinical features of the study population (n¼ 46)
Diagnosis N
Age at the sleep
study (years)
Ambulant
(n)
Scoliosis
(n)
Total 46 14.9 (11.9–17.1) 7 37
DMD 14 16.1 (14.9–17.4) 0 11
SMA 2 12 11.1 (7.4–15.5) 0 9
BMD 6 26 (15–34) 3 3
CM 9 13.9 (9.2–14.6) 3 9
Nemaline myopathy 6 3 6
Fibre disproportion/central core 3 0 3
CMD 14.3 (6.4–15.1)
Ullrich disease 5 1 5
DMD¼Duchenne muscular dystrophy, SMA 2¼ spinal muscular atrophy type 2, BMD¼Becker muscular
dystrophy, CM¼ congenital myopathy, and CMD¼ congenital muscular dystrophy.
1156 Journal of International Medical Research 46(3)
Discussion
The diagnosis of nocturnal hypoventilation
is not simple in neuromuscular diseases,
and to date, many different definitions
have been suggested.3,14 In this study, we
used the definition proposed by the
American Academy of Sleep Medicine,
N=46
29 NH 17 no NH
13 NH isolated
hypercapnia
6 NH and 
hypoxemia
23 NH without
hypoxemia
7 NH and 
dayme 
hypercapnia
16 NH without
hypoxemia nor
dayme hypercapnia
3 NH and  
symptoms
Figure 1. Flow diagram outlining sleep study results according to detection of nocturnal hypoventilation,
the presence of significant hypoxemia, daytime hypercapnia, and daytime symptoms
Table 2. Comparison between baseline demographic and nocturnal results between patients
with NH and non-NH patients
Non-NH
(n¼ 17)
NH
(n¼ 29) p
Diagnosis
DMD 7 7
SMA 2 7 5
BMD 2 4
CM 0 9
CMD 1 4
Age (years) 16.3 7.1 14.9 6.6 0.55
FVC (% predicted) 42.8 10.3 30 10.5 0.007
Mean tcSpO2 (%) 97.5 0.9 96.2 1.5 0.02
Mean tcPCO2 (mmHg) 43.3 3.2 53.6 4.2 0.0001
Daytime PaCO2 rise (yes) 0 9 0.02
Daytime bicarbonate (mEq/l) 22.9 1.9 25.9 2.3 0.01
NH¼ nocturnal hypoventilation, DMD¼Duchenne muscular dystrophy, SMA 2¼ spinal muscular atrophy
type 2, BMD¼Becker muscular dystrophy, CM¼ congenital myopathy, and CMD¼ congenital muscular
dystrophy, FVC¼ forced vital capacity, tc¼ transcutaneous coupled.
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which defines hypoventilation as pCO2> 50
mmHg for> 25% of sleep time17,18 because
it is specifically tailored for the paediatric
population. Using this threshold, we
found that transcutaneous monitoring of
pCO2 levels could potentially detect noctur-
nal hypoventilation, even in asymptomatic
patients and those without significant noc-
turnal hypoxaemia. Twenty-three of 29
patients with NH did not have nocturnal
hypoxemia, and 18 were clinically asymp-
tomatic. Furthermore, in 20 of 29 patients
with NH, PaCO2 in daytime blood samples
was normal. Therefore, 13 of 29 patients
had isolated nocturnal hypercapnia that
was not associated with significant
nocturnal hypoxia, daytime hypercapnia,
or clinical NH symptoms. Notably, in our
population, four patients with BMD had
atypically severe muscular involvement
with early onset.19
These results highlight the importance of
taking into account the presence of noctur-
nal hypercapnia when deciding whether
non-invasive support is required. Our
study suggests that pulse oximetry alone is
insufficient for detecting nocturnal hypo-
ventilation in children with NMD without
obstructive sleep apnoea. The current
guidelines recommend that NIV should be
started in the presence of daytime hyper-
capnia and/or clinical symptoms.20,21
Nevertheless, we showed that both
of these factors may not be sensitive
enough in the diagnosis of NH in NMD.
Therefore, nocturnal transcutaneous moni-
toring of pCO2/SpO2 may help in the early
detection of nocturnal hypoventilation in
Table 4. Differences in respiratory involvement according to neuromuscular disease in patients with NH
(n¼ 29)
DMD SMA 2 BMD CM CMD p
Age at detection
of NH (y)
16.2 (14.9–17.5) 10.3 (8.1–17.5) 26 (18–31.4) 13.9 (9.1–14.6) 13.4 (3.4–15.5) 0.007
Baseline
tcSpO2 (%)
97 (97–97) 96 (95.3–97.5) 97 (97–97) 96 (93.5–96.5) 97 (93–98) 0.08
Baseline tcPCO2
(mmHg)
51.6 (51–53) 55 (53–57) 50.5 (50–57) 52.5 (50–57) 54.5 (52.5–56.5) 0.57
NH¼ nocturnal hypoventilation, DMD¼Duchenne muscular dystrophy, SMA 2¼ spinal muscular atrophy type 2,
BMD¼Becker muscular dystrophy, CM¼ congenital myopathy, and CMD¼ congenital muscular dystrophy.
Table 3. Comparison of gas exchange (tcPCO2 and tcSpO2), daytime clinical
symptoms, daytime bicarbonate levels, and PaCO2 values in patients with NH at
baseline and after 6 months of NIV treatment.
Baseline
On NIV
treatment p
NH symptoms (yes) 11/29 0/29 0.0003
Mean nocturnal tcSpO2 (%) 96.2 1.5 96.8 1.2 0.009
Mean nocturnal tcPCO2 (mmHg) 53.6 4.2 45.3 5.4 <0.0001
Daytime bicarbonate (mEq/l) 25.9 2.3 24.5 1.9 0.01
Daytime PaCO2 (mmHg) 50.8 7.9 48.7 10.2 0.03
NH¼ nocturnal hypoventilation, NIV¼ non-invasive ventilation.
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young NMD patients, even before the onset
of ventilatory deficiency and clinical symp-
toms. Nevertheless, we are aware that estab-
lishment of NIV support in the absence of
either clinical symptoms or impairment of
daytime gas exchange could have some dis-
advantages, such as a lack of adherence. In
our population, we did not experience such a
problem. However, notably, NIV support
was started at low pressures. We did not spe-
cifically collect objective data on NIV adher-
ence post-establishment. However, we did
not notice any differences in terms of subjec-
tive tolerance between the NH group and the
remainder of the patients. Moreover,
Raphael et al.22 reported that patients who
started NIV before the onset of daytime
symptoms had a worse outcome compared
with the control group. Despite this isolated
report, there have since been several studies
demonstrating how NIV support prolongs
survival in NMD.23 However, in our study,
we were not able to relate early detection of
NH and commencement of NIV with clini-
cally relevant outcomes because of the
absence of a control group. Our study also
confirmed previous findings that nocturnal
tcSpO2/tcPCO2 monitoring helped manage
and setup NIV support in home-ventilated
patients.24,25
To the best of our knowledge, our study
population is the youngest population of
NMD patients in whom transcutaneous CO2
data have been reported. A previous report
suggested that nocturnal transcutaneous
assessment of pCO2 was more reliable than
CO2 measured by morning arterial blood
gases.13 In contrast, Georges et al.15 reported
similar findings to our current data but their
study group included a much wider popula-
tion of respiratory restrictive disorders, not
only neuromuscular diseases. Finally, Ogna
et al.14 demonstrated the usefulness of
tcPCO2/SpO2 monitoring among the NH
diagnostic tools, and the need to better
define the threshold for NH itself. However,
none of these studies specifically addressed the
question of whether nocturnal monitoring can
be used as an additional tool in the decision to
start NIV in the clinical setting.
Our study has some limitations, such as
the inclusion of a heterogeneous NMD
population and the relatively small sample
size. Furthermore, because of the retrospec-
tive nature of the study, data regarding
muscle strength (maximum inspiratory
pressure and maximum expiratory pres-
sure), cough effectiveness (peak cough
flow), and lung volume in the supine posi-
tion were not available. Moreover, our
study specifically focussed on nocturnal
tcPCO2/SpO2 monitoring. We did not
include the results of overnight cardiorespi-
ratory polygraphic studies. The first reason
for not including these studies is because we
did not have complete data from cardiore-
spiratory studies in all of the patients. The
second reason is because the main purpose
of the study was not to compare tcPCO2/
SpO2 monitoring with respiratory polygra-
phy in detecting NH among patients with
NMD. Instead, we aimed to evaluate
whether nocturnal hypercapnia is present
in clinically asymptomatic NMD. Indeed,
we found that nocturnal oximetry, the pres-
ence of daytime symptoms, and daytime
hypercapnia could underestimate actual
impairment of nocturnal gas exchange.
In conclusion, we report the results of noc-
turnal tcPCO2/tcSpO2 monitoring in the
youngest population of patients with NMD
studied to date. Our study shows that mean
nocturnal SpO2 is not sufficient for early
detection of NH in NMD. Furthermore,
tcPCO2/SpO2 monitoring can help clinicians
in the setup of titrating NIV. Nevertheless,
prospective studies are required to clarify
whether early initiation of NIV for asymp-
tomatic NH has a beneficial effect on survival.
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